In this article, we evaluated the feasibility of the restricted replication -competent adenoviruses for treatment of anaplastic thyroid carcinomas ( ATCs ) , which are very aggressive and difficult to treat. Because ATCs very often harbor p53 mutations, we used wt -p53 as a regulatory factor to restrict virus replication and cytopathic effect to p53 -mutated cells. The recently reported``gene inactivation strategy'' using p53 -regulated Cre / loxP system was employed; this system consists of two recombinant adenoviruses. One has an expression unit of the synthetic p53 -responsive promoter and the Cre recombinase gene ( Axyp53RECre ) , and another contains two expression units; the first consists of E1A gene flanked by a pair of loxP sites downstream of the constitutive CAG promoter and the second E1B19K gene under the control of the CMV promoter ( AdCALE1AL ) . We expected that coinfection of these two adenoviruses into the cells with wt -p53 would lead to expression of the Cre, which excises E1A gene and switches off E1A expression resulting in no virus replication, whereas in the cells with mutant p53 E1A could be expressed that leads to virus replication and cell lysis. Our in vitro data demonstrate that although infection of AdCALE1AL alone led to E1A expression, viral replication and cytolysis in all the thyroid cells examined irrespective of their p53 status, the double infection did so in FRO cells ( p53 -null ATC ) but not in FRO cells stably expressing wt -p53 and normal thyroid cells with wt -p53. These data indicate that our double infection method may have a potential for treatment of ATC and probably also other p53 -defective cancer cells. Cancer Gene Therapy ( 2001 ) 8, 36 ± 44
T hyroid carcinomas, the most common endocrine malignancy, 1 are classified pathologically into differentiated and anaplastic ( undifferentiated ) types of thyroid follicular epithelial cell origin. Differentiated thyroid carcinomas generally show good long -term prognosis, whereas anaplastic thyroid carcinomas ( ATC ) , albeit rare, are aggressive and difficult to treat. 1 We have recently focused our interest toward the development of gene therapy for these two types of thyroid carcinomas. 2 ± 6 Specific and efficient expression of a therapeutic gene is a critical factor for successful gene therapy. The use of replication -defective viruses have proven ineffective for treatment of large solid tumors, because of relatively low levels of vector delivery and gene transfer. To overcome this problem, replication -competent viruses have recently been utilized. 7 For such viruses, appropriate tumor targeting is a major challenge. Tumor-or tissue -specific promoters, such as alpha -fetoprotein (AFP ) and carcinoembryonic antigen, have been shown to be useful tools for selective expression of a therapeutic gene in cancer cells. 8 Our recent studies have also demonstrated the feasibility of thyroglobulin ( TG ) promoter, a thyroidspecific promoter, for transcriptionally targeted gene therapy of differentiated thyroid carcinomas expressing TG. 2, 3 However, ATCs express little or no TG, 1 indicating that use of thyroid -specific promoter (s ) is only applicable to a limited type of thyroid carcinoma.
Instead, as for cancer of any tissue origin, 9 ATCs very often harbor the mutations in tumor suppressor gene p53. 10 ± 12 Several approaches for gene therapy targeting tumors with mutant p53 have been described. Restoration of wt -p53 expression by introducing wt -p53 gene is probably the simplest and most straightforward approach for such tumors. Viral -mediated wt -p53 gene introduction has widely been used as a cancer gene therapy in numerous experimental cancer models and also in human clinical trials. 13, 14 The efficacy of wt -p53 gene therapy for ATC has recently been shown by us 6 and other groups. 15 Further-more, such a characteristic of key molecule can also be used for discrimination between normal and cancer cells. Thus, novel strategies for gene therapy of p53-mutated cancer cells have been recently described. Adenovirus lacking E1B55K is such an example, which has been demonstrated to preferentially replicate in and lyse tumor cells with p53 mutations, 16 ± 18 although some recent articles have described the controversial data. 19 ± 25 Furthermore,`g ene -inactivation strategy'' using``p53 -regulated Cre / loxP system'' has also been recently reported, in which the p53 -responsive promoter and Cre / loxP system were used to target the expression of a therapeutic gene to tumor cells with p53 mutations. 26 The present studies were designed to establish the efficacious gene therapy for ATC using replication-competent adenoviruses. We first elucidated the therapeutic efficacy of adenovirus lacking E1B55K for ATC. Our data, however, demonstrated p53-independent cytopathic effect of adenovirus lacking E1B55K 27 in normal and cancerous thyroid cells ( our unpublished data ) . Therefore, we next took advantage of the above -mentioned``gene -inactivation strategy'' with p53-regulated Cre/ loxP system to strictly restrict the replication of adenovirus to the cells without functional p53.
MATERIALS AND METHODS

Cells used
A human ATC cell line expressing no detectable p53 ( FRO ) was provided by J. A. Fagin ( University of Cincinnati College of Medicine, Cincinnati, OH ) and grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS ) and ampicillin /streptomycin. FRO cells stably expressing wt-p53 (FRO -p53 ) has previously been established. 28 Thyroid tissue samples were obtained by subtotal thyroidectomy from patients with Graves' disease, and normal human thyroid follicular cells in primary culture were prepared as previously described 29 and maintained in Ham's F12 medium with 5% FBS and antibiotics. Informed consent was obtained from each patient. 293 human embryonic kidney (293 HEK ) cells were obtained from American Type Culture Collection ( ATCC, Manassas, VA ) and were cultured in Dulbecco's modified Eagle's medium with 10% FBS and antibiotics.
Recombinant adenoviruses
The recombinant adenoviruses used in the present study are shown in Figure 1 . The recombinant adenovirus AdCA-LE1AL ( Fig 1 ) , in which E1A gene was flanked by a pair of loxP and was placed under the control of the constitutive CAG promoter 30 and E1B19K gene was under the control of CMV promoter, was constructed as previously described. 31, 32 Briefly, E1A gene in pBlueScript was excised with EcoRI/ BamHI followed by blunt -ending and ligated into the SwaI site of pCALwL 33 to yield pCALE1AL.The direction of the insert was confirmed by restriction enzyme digestions. pCMV19K 34 was digested by ClaI/BamHI to release the DNA fragment containing CMV promoter, E1B19K gene, and SV40 polyadenylation signal. This DNA fragment was blunt -ended and ligated into pCA-LE1AL that had been digested with PstI and blunt -ended, resulting in pCALE1ALCMV19K. SalI/HindIII -digested pCALE1ALCMV19K was ligated into SalI/HindIIIdigested pHM5. 31 The resultant plasmid pHM5CA-LE1ALCMV19K was then digested with I-CeuI/PI-SceI and ligated into I-CeuI/PI-SceI± digested pAdHM4. NAGAYAMA, NISHIHARA, NAMBA, ET AL: ANAPLASTIC THYROID CANCER GENE THERAPY and transfected into 293 cells with SuperFect (Qiagen, Tokyo, Japan ) according to the manufacturer's instructions. Recombinant adenovirus was then plaque -purified.
Constructions of replication -deficient, E1 / E3 -deleted recombinant adenovirus vectors, AxCAyCre, Axyp53RECre, AxCAyp53, AxCAyLLZL, AxCAyLTKL, and AxCALacZ have also been previously described. 26, 33 AxCAyCre, AxCAyp53, and AxCALacZ contain the Cre recombinase gene, wt-p53 cDNA, and LacZ gene, respectively, under the transcriptional control of the CAG promoter. Axyp53RECre has the Cre recombinase gene under the transcriptional control of eight tandem copies of the consensus p53-binding sequence ( p53RE; 5 H -GGA CTT GCC TGG ACT TGC CT-3 H ) followed by the SV40 basic promoter. AxCAyLLZL and AxCAyLTKL contain the LacZ gene and herpes simplex virus thymidine kinase ( HSV-TK ) gene, respectively, which are inserted between two loxP sequences located downstream of the CAG promoter.
Adenovirus was propagated in 293 HEK cells and purified through two rounds of CsCl density gradient centrifugation. 35 The multiplicity of infection (MOI) was defined as the ratio of total number of plaque -forming units ( pfu ) used in a particular infection per number of cells. Adenovirus titers were determined by plaque formation after infection into 293 HEK cells.
Virus replication
The cells were seeded in 12 -well culture plates at a density of (5 ±10 )Â10 4 cells /well and were infected with adenoviruses at the MOI indicated. The cells and super- natants were collected 5 days later. The titer of adenovirus was determined by the plaque -forming assay with 293 HEK cells.
X -gal staining
The cells, seeded at (1 to 3 ) Â10 5 cells/well in 24-well culture plates, were infected with adenoviruses at the MOI indicated. Two days later, the cells were stained with 5-bromo-4-chloro -indolyl --D -galactopyranoside ( x-gal ) as previously described. 3 
-Galactosidase activity
The cells, seeded at ( 5 to 7 )Â10 5 cells /well in six -well culture plates, were infected with adenoviruses at the MOI indicated. Two days later, the cells were harvested after washing with phosphate -buffered saline three times and then resuspended with 0.25 M Tris ± HCl (pH 7.8) . Following treatment with ultrasound and centrifugation at 12,000Âg for 5 minutes, the -galactosidase activity was measured as described 36 using o-nitrophenyl --D -galactopyranoside as a substrate.
Cytopathic effect
The cells, seeded at a density of (1 to 2) Â10 3 /well in 96-well microtiter plates, were infected with adenoviruses at the MOI indicated. Cell viability was quantitated 1, 3, and 5 days later with a WST-1 assay ( cell -counting kit; Wako, Osaka, Japan ) .
Ganciclovir ( GCV ) cytotoxicity
The cells, seeded at (1 to 3 ) Â10 3 cells/well in 96-well microtiter plates, were infected with adenoviruses at the MOI indicated. Then, the cells were treated with various concentrations of GCV (Hoffman -La Roche, Basel, Switzerland) in 100 L of medium for 4 days. Cell survival was quantitated as described above.
Immunoblot for E1A protein expression
A total of 5Â10 5 cells in six -well culture plates were infected with adenoviruses at the MOI indicated. After various incubation times, the total cell lysate was prepared and 40 g protein was subjected to immunoblot analysis in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis ( SDS -PAGE ) under denaturing and reducing conditions with anti-E1A monoclonal antibody ( M73, Santa Cruz Biotechnology, Santa Cruz, CA ) and alkaliphophatase ABC kit (Vectastain ABC kit, Vector Laboratories, Burlingame, CA ) .
RESULTS
Efficacy of p53 -regulated Cre / loxP system`G ene-inactivation strategy'' with p53 -regulated Cre / loxP system 26 has recently been established to exclusively express a gene of interest ( GOI ) in p53-deficient cells. This strategy consists of two recombinant adenoviruses ( Fig 1B) . One adenovirus (regulatory adenovirus ) expresses the Cre recombinase gene under the transcriptional control of p53-responsive promoter containing tandem repeats of eight consensus p53 -binding domains and SV40 basic promoter. Another adenovirus (expression adenovirus ) contains GOI flanked by a pair of loxP sequences downstream of the constitutive CAG promoter. Coinfection of these two adenoviruses direct p53-intact cells to produce the Cre recombinase, which excises GOI flanked by two loxP sites, leading to shut -off of the expression of GOI. In contrast, tumor cells without functional p53 fail to produce the Cre recombinase and express GOI.
We first verified the efficacy of``gene -inactivation strategy'' with p53-regulated Cre/ loxP system using AxCAyLLZL, Axyp53RECre, and AxCAyCre ( Fig 1 ) in a pair of isogenic cell lines that differs only in their p53 28 ] and normal human thyroid cells with wt -p53. AxCAyLLZL was infected alone or in combination with Axyp53RECre or AxCAyCre into thyroid cells, and LacZ expression levels were assessed by x-gal staining and -galactosidase assay ( Fig 2A and B ) . In FRO -p53 and normal thyroid cells, -galactosidase activity was clearly decreased by coinfection with Axyp53RECre in a dose -dependent manner. In contrast, in coinfected FRO cells -galactosidase activity was somewhat decreased only when the high MOI ( = 30 ) of Axyp53RECre was used. However, coinfection of AxCAyCre and AxCAyLLZL showed clear suppression of the staining in FRO cells.
HSV-TK gene was also used for evaluating the efficacy of this strategy. The cells were coinfected with Axyp53RECre and AxCAyLTKL at various ratios and treated with GCV. As shown in Figure 3 , infection of AxCAyLTKL alone rendered FRO and normal thyroid cells sensitive to GCV. Coinfection with Axyp53RECre and AxCAyLTKL showed little, if any, decrease in sensitivity to GCV in FRO cells. However, sensitivity of normal thyroid cells to GCV was clearly decreased by coinfection with Axyp53RECre in a dose -dependent manner. These data indicate p53 status -dependent expression of the Cre recombinase and the efficient excision of GOI by the Cre.
Therapeutic efficacy of AdCALE1AL
To use``gene -inactivation strategy'' with p53 -regulated Cre /loxP system for targeting the replication of adenovirus to p53 -defective ATC, we constructed the new adenovirus vector, AdCALE1AL, in which E1A gene was placed between a pair of loxP sequences, whose transcription is under the control of the CAG promoter. We expected that double infection of AdCALE1AL and Axyp53RECre into the cells with wt -p53 would lead to expression of the Cre recombinase, which excises E1A gene and shuts off E1A expression resulting in no virus replication, whereas in the cells with mutant p53 E1A could be expressed, which leads to virus replication and cell lysis.
To evaluate the regulation of E1A gene expression from AdCALE1AL by the Cre recombinase, FRO cells were first infected with AdCALE1AL alone or in combination with AxCAyCre. When AdCALE1AL was used alone, E1A expression was detected 8 hours after infection and reached a plateau 24 hours after infection (Fig 4A, lanes 2 to 6) . However, when the cells were infected with these two adenoviruses at a ratio of 10:10 (MOI) simultaneously ( lanes 7 to 11 ) or infected first with AxCAyCre and then AdCALE1AL at a 24 -hour interval (lanes 12 to 16) , E1A expression was almost completely suppressed, indicating the high efficacy of the p53 -regulated Cre / loxP system to regulate E1A expression.
Axyp53RECre was used in the next experiments. In coinfection of AdCALE1AL and Axyp53RECre at a ratio of 10:100 ( MOI ) into FRO cells, E1A expression level was as high as that in the cells infected with AdCALE1AL alone at an MOI of 10 ( Fig 4B, lanes 1 to 4 ) . In contrast, E1A expression was suppressed by Axyp53RECre coinfection in a dose -dependent manner in FRO -p53 cells (lanes 5 to 12) . However, the suppression was incomplete even when Axyp53RECre infection was performed 1 day before at a high ratio of Axyp53RECre to AdCALE1AL ( 100:10 ) . This is probably because expression level of the Cre recombinase through the p53 -responsive promoter is weaker than that through the constitutive CAG promoter.
Replication of AdCALE1AL was then evaluated by two types of assays: ( a) virus titrations and (b ) -galactosidase assay. AdCALE1AL replicated well in all the cells with $550 -to $900-fold increase in virus titers in 5 -day culture, which was clearly inhibited by simultaneous infection with AxCAyCre in all the cells ( Fig 5A ) . Consistent with E1A immunoblot, prior infection of Axyp53RECre inhibited the virus replication in a dose -dependent manner in FRO ± p53 and normal cells, but not in FRO cells. Similarly, in -galactosidase assay (Fig 5B ) , double infection of AxCALacZ and AdCALE1AL significantly increased the enzyme activity compared to a single infection of AxCALacZ. This increase was almost completely suppressed by simultaneous infection of AxCAyCre (10:10 ) in all the cells, whereas dose -dependent suppression of the enzyme activity by prior infection of Axyp53RECre was only observed in FRO ± p53 and normal thyroid cells.
Finally, the cytopathic effect of AdCALE1AL infection was determined ( Fig 6 ) . Infection of AdCALE1AL at an MOI of 10 for 5 days killed comparably both FRO and normal cells. Again, this killing effect was significantly inhibited by coinfection of AxCAyCre in both cells, but dose -dependent inhibition by Axyp53RECre was observed only in normal thyroid cells.
These data all together indicate the selective replication and induction of cytopathic effect by coinfection of 
DISCUSSION
The present studies were designed to evaluate the therapeutic efficacy of the restricted replication -competent adenoviruses for treatment of ATC. It is well known that 70 ± 85% of ATC have the mutations in tumor suppressor gene p53.
10 ± 12 We here used wt -p53 as a regulatory factor, not as a therapeutic agent, for restricting virus replication to p53 -mutated cells. The first restricted -replication competent adenovirus we used was adenovirus lacking E1B55K, which, however, showed p53 -independent cytopathic effect in thyroid cells ( unpublished data ) .
Therefore,``gene inactivation strategy'' with p53-regulated Cre / loxP system 26 was used to strictly confine the virus replication to p53 -mutated cells. Because our preliminary experiments with AxCAyLLZL, AxCAyLTKL, and Axyp53RECre revealing the efficient regulation of expression of LacZ and HSV-TK genes by p53 (see Fig 2 and 3) was promising, a new adenovirus was constructed in which E1A gene was placed between a pair of loxP sequences iǹ`e xpression adenovirus'' ( see Fig 1 ) . Our data clearly demonstrate wt -p53± dependent suppression of replication and cytopathic effect of AdCALE1AL in the cells with wtp53. Although the synthetic p53-responsive promoter we used here is not completely silent in p53 -null FRO cells infected with the high MOI of Axyp53RECre ( see Fig 2A ) and the suppression by Axyp53RECre was somewhat less prominent compared to that by AxCAyCre in the cells with wt -p53 ( see Fig 4 ) probably because the p53 -responsive promoter we used is not strong enough to induce the sufficient amounts of the Cre recombinase, our data clearly demonstrate the feasibility of AdCALE1AL and Axyp53RECre double -infection method for ATC gene therapy.
Besides replication -mediated cytolysis, another advantage of the use of replication -competent adenovirus is expression of E1A protein, which is reported to exert antineoplastic effect by inducing apoptotic cell death. 37, 38 Furthermore, virus -mediated lysis of tumor cells may release tumor antigens, thereby augmenting antitumor immunity. 39 However, single modality of gene therapy with replicationcompetent adenovirus alone may not elicit enough antitumor effect. 40 Because synergistic interaction of replicationcompetent adenovirus and standard chemotherapeutic agents 17, 41, 42 or suicide /cytokine gene therapies 27,43 ± 45 has been reported, further studies will be needed for finding the most efficacious combination for treatment of ATC.
Replication -competent microbiological agents including adenovirus have recently gained much attention. 7 Targeting of replication of adenovirus has been achieved not only by E1B55K deletion but also by using tumor-(or tissue ) -specific promoters such as AFP, prostate -specific antigen and kallikrein 2.
46 ± 48 Further, Zhu et al 49 have successfully used the heat shock protein 70 gene promoter, whose activity is suppressed by wt -p53, to target the expression of a therapeutic gene to tumor cells with p53 mutations.
However, in the present study and also the report of Zhu et al, 49 transduction of two vectors into each cell is a crucial point for the system to operate properly. Particularly in an in vivo situation, p53-intact normal cells, if not infected with Axyp53RECre, would support replication of AxCALE1AL in our system. This concern comes from the facts that ( a) infectivity of intratumoral injection of recombinant adenovirus is generally low in vivo, and also ( b) estimated MOIs achieved following intratumoral injection of adenovirus may be lower than those used in this study. Although we have previously demonstrated in vivo usefulness of``gene activation strategy'' using Cre/ loxP system and TG promoter in differentiated tyroid cancers, 3 it will be required to evaluate in vivo efficacy of this``gene inactivation strategy'' with p53-regulated Cre / loxP system. Finally, we here show the in vitro therapeutic efficacy of our p53-mutated cell -specific replication-competent adenovirus in ATC. However, it is worthy noting that this strategy can be applied to many p53 -mutated cancers derived from various tissues, because p53 mutations are observed in a wide range of human cancers at very high incidence. 9 
